21253-62-3

Basic information

• Product Name: ethyl 5-amino-1-cyclohexyl-1H-pyrazole-4-carboxylate
• CAS NO: 21253-62-3
• Molecular Formula: C₁₂H₁₉N₃O₂
• Molecular Weight: 237.2982
• Mol File: 21253-62-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 392.6°C at 760 mmHg
• Flash Point: 191.2°C
• Density: 1.28g/cm³
• Vapor Pressure: 2.27E-06mmHg at 25°C
• Refractive Index: 1.609
• CAS DataBase Reference: ethyl 5-amino-1-cyclohexyl-1H-pyrazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-amino-1-cyclohexyl-1H-pyrazole-4-carboxylate(21253-62-3)
• EPA Substance Registry System: ethyl 5-amino-1-cyclohexyl-1H-pyrazole-4-carboxylate(21253-62-3)

Safety Data

• Hazardous Substances Data: 21253-62-3(Hazardous Substances Data)

Upstream product

• 42466-67-1 ethyl (ethoxymethylene)cyanoacetate 
• 6498-34-6 cyclohexylhydrazine 
• 24214-73-1 cyclohexylhydrazine hydrochloride 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 108-85-0 1-bromocyclohexane 
• 6994-25-8 3-amino-4-pyrazolecarboxylic acid ethyl ester 
• 94-05-3 2-cyano-3-ethoxyacrylic acid ethyl ester 

Downstream Products

• 950859-24-2 5-chloro-1-cyclohexyl-1H-pyrazole-4-carboxylic acid ethyl ester 
• 3528-50-5 1-cyclohexyl-1H-pyrazol-5-amine 
• 1023301-92-9 (5-amino-1-cyclohexylpyrazol-4-yl)-N-(4-methoxyphenyl) carboxamide 

Relevant articles and documents

The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition

In this study, a series of sulfonamide compounds was designed and synthesized through the systematic optimization of the antibacterial agent sulfaphenazole for the treatment of Mycobacterium tuberculosis (M. tuberculosis). Preliminary results indicate that the 4-aminobenzenesulfonamide moiety plays a key role in maintaining antimycobacterial activity. Compounds 10c, 10d, 10f and 10i through the optimization on phenyl ring at the R2 site on the pyrazole displayed promising antimycobacterial activity paired with low cytotoxicity. In particular, compound 10d displayed good activity (MIC = 5.69 μg/mL) with low inhibition of CYP 2C9 (IC50 > 10 μM), consequently low potential risk of drug-drug interaction. These promising results provide new insight into the combination regimen using sulfonamide as one component for the treatment of M. tuberculosis.

Substituted pyrazolopyrimidines

The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R1, R2, R3, R4, R5, X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).

Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.